THE EFFECTS OF ENALAPRIL ON NOCTURNAL BLOOD PRESSURE DIPPING

依那普利对夜间血压下降的影响

• 批准号: 7608246
• 负责人: PHYLLIS W SPEISER
• 金额: $ 0.29万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608246
• 关键词: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitors; Class; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Elevation; Enalapril; Enalapril Maleate; Funding; Grant; Hour; Institution; Kidney; Measures; Microalbuminuria; Pattern; Pharmaceutical Preparations; Placebos; Proteins; Randomized; Research; Research Personnel; Resources; Risk Factors; Signal Transduction; Source; United States National Institutes of Health; Urine; Week; diabetic; monitoring device; nephrogenesis; type I diabetic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Damage to the kidneys can occur after many years of diabetes. Blood pressure (BP) elevation has repeatedly been shown to represent a risk factor for the early development of kidney damage. Studies have shown that the loss of the normal nocturnal BP dipping pattern may signal the development of early kidney damage by preceding the development of microalbuminuria. A class of medications, called angiotensin converting enzyme (ACE) inhibitors, specifically enalapril maleate has been shown to decrease microalbuminuria in the urine of diabetics. Using ambulatory blood pressure monitoring device, type-1 diabetics who have lost normal nocturnal BP dipping pattern and do not have evidence of microalbuminuria will be randomized to be treated with enalapril or placebo for 12 weeks. Thereafter their 24-hour BP and urine analysis will be re-measured to see if the treatment with enalapril can re-establish the normal nocturnal BP dipping pattern. It is hypothesized that if nocturnal dipping pattern can be re-established, this may delay onset of protein in the urine and drastic kidney damage.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 糖尿病多年后可能会对肾脏造成损害。血压（BP）升高已多次被证明是肾损伤早期发展的危险因素。研究表明，正常夜间血压下降模式的丧失可能预示着微量白蛋白尿的发生，从而导致早期肾损伤的发生。一类药物，称为血管紧张素转换酶（ACE）抑制剂，特别是马来酸依那普利已被证明可以减少糖尿病患者尿液中的微量白蛋白尿。 使用动态血压监测装置，失去正常夜间BP下降模式且没有微量白蛋白尿证据的1型糖尿病患者将随机接受依那普利或安慰剂治疗12周。 此后，将重新测量他们的24小时血压和尿液分析，以观察依那普利治疗是否可以重新建立正常的夜间血压下降模式。 据推测，如果夜间浸渍模式可以重新建立，这可能会延迟尿中蛋白质的发生和严重的肾损伤。